The two companies first started collaborating on diabetes technology in 2021. The acquisition is not yet final, but Novo Nordisk now holds the exclusive negotiation rights.
Findings from the SOLVE-CRT study were presented to attendees at Heart Rhythm 2023. "Our results showed the study was safe, effective and feasible," Singh said.